{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:23Z","timestamp":1793155823724,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jdermsci.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T21:26:22Z","timestamp":1551993982000},"page":"176-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A novel ROR\u03b3t inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations"],"prefix":"10.1016","volume":"93","author":[{"given":"Chihiro","family":"Imura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azumi","family":"Ueyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Furue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michitaka","family":"Shichijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2019.03.002_bib0005","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Sch\u00f6n","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0010","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0025","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010179","article-title":"Scanning the immunopathogenesis of psoriasis","volume":"19","author":"Chiricozzi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0035","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.1073\/pnas.97.18.10132","article-title":"Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis","volume":"97","author":"Kurebayashi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0040","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1126\/science.288.5475.2369","article-title":"Requirement for RORgamma in thymocyte survival and lymphoid organ development","volume":"288","author":"Sun","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0045","first-page":"901","article-title":"High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor RORgamma","volume":"62","author":"Ueda","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0050","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.autrev.2016.07.036","article-title":"Retinoid-related orphan receptor \u03b3 (ROR\u03b3) adult induced knockout mice develop lymphoblastic lymphoma","volume":"15","author":"Liljevald","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91127","article-title":"Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations","volume":"2","author":"Guntermann","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0060","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.celrep.2016.11.073","article-title":"Inhibition of ROR\u03b3T skews TCR\u03b1 gene rearrangement and limits T Cell repertoire diversity","volume":"17","author":"Guo","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/srep37977","article-title":"Pharmacologic modulation of ROR\u03b3t translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis","volume":"6","author":"Xue","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0070","article-title":"Development of a topical treatment for psoriasis targeting ROR\u03b3: from bench to skin","volume":"11","author":"Smith","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdermsci.2016.10.001","article-title":"Oral administration of a novel ROR\u03b3t antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17","volume":"85","author":"Takaishi","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0080","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.bmcl.2018.09.032","article-title":"Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (ROR\u03b3t) inhibitor, S18-000003","volume":"22","author":"Sasaki","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdermsci.2016.10.007","article-title":"Potential role of IL-17-producing CD4\/CD8 double negative \u03b1\u03b2 T cells in psoriatic skin inflammation in a TPA-induced STAT3C transgenic mouse model","volume":"85","author":"Ueyama","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0090","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.0902796","article-title":"IL-23 receptor regulates unconventional IL-17-producing T cells that control bacterial infections","volume":"184","author":"Riol-Blanco","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0095","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crisp\u00edn","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2012-201511","article-title":"IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren\u2019s syndrome","volume":"72","author":"Alunno","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl","key":"10.1016\/j.jdermsci.2019.03.002_bib0105","doi-asserted-by":"crossref","first-page":"12s","DOI":"10.1111\/1523-1747.ep12536743","article-title":"Skin-associated lymphoid tissues (SALT): origins and functions","volume":"80","author":"Streilein","year":"1983","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0110","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ni.2992","article-title":"Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin","volume":"15","author":"Natsuaki","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0115","doi-asserted-by":"crossref","first-page":"10723","DOI":"10.1073\/pnas.1307569110","article-title":"Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice","volume":"110","author":"Wohn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0120","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2014.98","article-title":"IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing \u03b3\u03b4 T cells","volume":"134","author":"Yoshiki","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaci.2010.12.009","article-title":"Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17\/TH1 T-cell responses","volume":"127","author":"H\u00e4nsel","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2019.03.002_bib0130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/0019-5154.139872","article-title":"Topical steroid-damaged skin","volume":"59","author":"Abraham","year":"2014","journal-title":"Indian J. Dermatol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119300672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119300672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:49:31Z","timestamp":1760330971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181119300672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0923181119300672"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.03.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel ROR\u03b3t inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}